25 Year Industry Veteran to Focus on Continued Development of Breast and Endometrial Applications and New Novel Markets for the Axxent(R) Electronic Brachytherapy System
SUNNYVALE, Calif., June 18 /PRNewswire/ -- Xoft, Inc., makers of theAxxent(R) Electronic Brachytherapy System, a proprietary technology platformdesigned to deliver localized, non-radioactive, isotope-free radiationtreatment in minimally-shielded clinical settings, announced today that MarkCarol, MD, has joined as Chief Medical Officer. Bringing more than 25 yearsof clinical practice and medical device industry experience to Xoft, Dr. Carolwill focus on continued development of the current breast and endometrialcancer applications as well as explore future indications and markets based onthe ability to deliver KV energy anywhere in the body.
'I have spent most of my career working to develop and deliver noveltherapies to patients that have clear-cut clinical value, but do not cost themor the healthcare system an arm and a leg,' said Dr. Carol. 'I am excited tojoin Xoft and be part of a talented team dedicated bringing a dramatic newapproach to the delivery of radiation treatment that I believe can lead tofundamental breakthroughs in cancer research and treatment and, perhaps mostimportantly, patient care.
'While Electronic Brachytherapy has already demonstrated clear clinicalvalue in the treatment of breast and is now being applied to endometrialcancers, the energy range the technology operates in opens the doors to amyriad of new treatment options and modalities. For example, intraoperativeradiation therapy has had many champions over the years; however, without atruly portable system to deliver a safe and consistent dose, it has not beenclinically or commercially practical. Binary therapy, known asphotoactivation or Disease Activated Radiation Therapy, is another applicationwell suited to this technology. If we can tag cancer cells with a materialsuch as iodine that can be activated by KV energy, we have the potential tovery effectively kill the cancer cells with little or no effect on thesurrounding healthy cells,' added Dr. Carol.
Dr. Carol, who recently received the Ira Sohn Conference Foundation Prizein Pediatric Oncology for his research on the use of KV X-ray-based radiationtherapy, previously served as a consulting medical director for Xoft. Hereceived his M.D. with distinction from University of Rochester in 1978, andwent on to complete a residency in neurosurgery at the University of Maryland.After spending four years in clinical practice, Dr.
